Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The USFDA has approved Amarin supplemental new drug application for Chemport as additional Vascepa active pharmaceutical ingredient supplier.
Subscribe to our email newsletter
The approval adds to the company’s planned expansion of the Vascepa manufacturing supply chain and expansion of patent protection for Vascepa in the US.
Amarin chairman and chief executive officer Joseph Zakrzewski said the sNDA approval of Chemport expands the company’s global supply chain to reach expected Vascepa demand, diversify supply base, and ensure cost-efficient supply.
"The addition of Chemport as an approved API supplier supplements Amarin’s current proven API supply source, Nisshin Pharma, Inc.," Zakrzewski added.